Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Status:
Terminated
Trial end date:
2019-08-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD), activity, and
safety of oprozomib in patients with hematologic malignancies.